GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-13 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
=== Continued unrest === Over Christmas, the UDF called for supporters to observe a "Black Christmas" – a form of consumer boycott, among other things – to mourn the casualties. This led to a fortnight of "comparative calm", excepting a large-scale confrontation on Christmas Day in Sharpeville, where a large crowd had clashed with police after returning from a Black Christmas event at the graves of those killed. Violence broke out again in PWV after Boxing Day. Morale was boosted by the successes of the Vaal uprising – the government had been forced to make certain concessions, removing local councillors to safety and suspending the rent increases – and militant vigour was piqued both by the severe state response and by the presence of troops in the townships, taken by some as a "declaration of war". The increased presence of state security forces in the townships led to a proliferation of opportunistic violence against the forces' members, who – if present in small enough numbers, or if they had run out of ammunition – became a frequent target for stone-throwing. One account describes young militants developing elaborate strategies to obstruct the security services' work: digging trenches to prevent armoured vehicles from moving around, blocking roads with burning tyres and rocks, painting over house numbers and other identifiers to stop police from identifying activists' houses, and staking out "liberated areas" where police and other state representatives could not go.
== References == This article was adapted from the following source under a CC BY 4.0 license (2021) (reviewer reports): Yingxuan Ma; Kim Johnson (2021). "Arabinogalactan-proteins" (PDF). WikiJournal of Science. 4 (1): 2. doi:10.15347/wjs/2021.002. Wikidata Q99557488.
Contamination has also been seen in water wells and other sources of drinking water. This contamination is seen in US, United Kingdom, Germany, Japan, and Canada, but information from most developing countries is nearly nonexistent. The lack of information on PFAS contamination in developing countries, especially those in Africa, are due to structural socioeconomic inequality and lack of access to the expensive laboratory capabilities required for PFAS quantification.
=== Secondary and tertiary structures === Chymopapain's structure was solved by X-ray diffraction techniques. Analysis of this structure showed chymopapain to have 7 alpha helix regions, 10 beta sheet regions and 2 loop turns. These 2 turns are the main difference between chymopapain's structure and other papaya proteinase proteins such as papain or caricain, which have similar conformations. Besides, chymopapain presents 3 disulfide bonds as post-traducional modifications stablished between residues 156–197, 190–229 and 287–338.
Sources: en.wikipedia.org
Through the late 1950s and early 1960s, numerous papers were published on various topics in RNA structure, including RNA-DNA hybridization, triple stranded RNA, and even small-scale crystallography of RNA di-nucleotides—G-C, and A-U—in primitive helix-like arrangements. For a more in-depth review of the early work in RNA structural biology, see the article The Era of RNA Awakening: Structural biology of RNA in the early years by Alexander Rich.
Robert Derek Channon (born 15 June 1944) is a British engineer known for inventing an insulin pump for diabetics, and miniaturized helicopters for the UK military. A diabetic himself, Channon developed the three ounce insulin pump to replace his own regular insulin injections. The National Medical Research Foundation awarded Channon £26,000 to develop the pump. In 1980, the National Medical Research Foundation awarded Guy's Hospital £40,000 to test Channon's pump in people with diabetes. The trial, under the supervision of Harry Keen, tested whether using the pump reduced the development of blindness in 30 people with diabetes. In July 2024 Channon was awarded an honorary Doctor of Engineering degree, by UWE Bristol, in recognition of his contribution to the management of type 1 diabetes.
Authentic extracts elevated to the rank of originals (Series A); Declarations by individuals (Series B); Official reconstructions based on documents held by the administration or registers transferred to it (Series C). This operation lasted until 1897 and ended due to a lack of funds. It made it possible to restore slightly more than 2.6 million records, most of which date from the 19th century. Only 347,000 records were restored for the Ancien Régime, with just five dating back to the 16th century. Altogether, the restored documents represent only one-third of those that were destroyed. Birth records are the most numerous, with approximately 1,422,000 records dating from 1550 to 1859, compared to around 922,000 death records from 1568 to 1859 and 322,000 marriage records from 1630 to 1859. However, the vast majority of data, particularly that concerning families without descendants, is lost forever. The reconstructed records are preserved at the Archives of Paris. Their duplicates, stored at the Montlignon Fort (Val-d’Oise), were destroyed in a fire in June 1974.
== Animals == Unlike in plants, animals do not have a pathway for the direct assimilation of inorganic sulfate into organic compounds. In animals, the primary source of sulfur is dietary methionine, an essential amino acid that contains a sulfur atom. Methionine is first converted to S-adenosylmethionine (SAM), a compound that is involved in many important biological processes, including DNA methylation and neurotransmitter synthesis. SAM can then be used to synthesize other important sulfur-containing compounds such as cysteine, taurine, and glutathione. Cysteine is a precursor for the synthesis of several important proteins and peptides, as well as glutathione, a powerful antioxidant that protects cells from oxidative stress. Taurine is involved in a variety of physiological processes, including osmoregulation, modulation of calcium signaling, and regulation of mitochondrial function.
In the BATT trial, growth velocity was decreased, bone age advancement was slowed, aggressiveness was decreased, and masculinization, measured via Tanner staging of pubic hair and genitals, did not appear to further progress. However, the decrease in growth rate was modest and fell just short of reaching statistical significance (p = 0.053). Conversely, although the decrease in rate of bone maturation was described as modest similarly, the ratio of bone age to chronological age was significantly reduced (p < 0.0001). Linear growth and skeletal maturation during normal puberty is mainly due to estradiol and not testosterone in both boys and girls, and hence inhibition of these processes with the combination of bicalutamide and anastrozole in precocious puberty would in theory be mostly dependent on the aromatase inhibitor rather than on bicalutamide. Testicular volume increased mildly over the year that the boys were observed. A New Drug Application of bicalutamide for FMPP in the United States was submitted on the basis of the BATT trial data. However, the application was not approved by the Food and Drug Administration, which cited insufficient evidence of effectiveness. Although indication of bicalutamide for the use was not granted, the bicalutamide medication label was updated to include the findings of the study. In terms of side effects, the combination of bicalutamide and anastrozole in the study was described as well tolerated with no safety concerns. However, gynecomastia, attributed to bicalutamide, was observed in almost half of the boys.
Sources: en.wikipedia.org
Although it has expanded outward from its original geographic base, most new restaurants are located in suburban areas of the Southern US. Since 1997, the Atlanta-based company has sponsored the Peach Bowl, an annual college football bowl game played in Atlanta on New Year's Eve. Chick-fil-A also sponsors the Southeastern Conference and the Atlantic Coast Conference of college athletics. In 2008, Chick-fil-A was among the first fast-food restaurants to become completely free of trans fats. In October 2015, the company opened its largest restaurant, a three-story 5,000 square feet (460 m2) restaurant in Manhattan.
=== Portuguese === Luso-American Financial - A Fraternal Benefit Society - Founded in 1868 as the Portuguese Protective and Benevolent Association of the City and County of San Francisco. Grand Council, most likely a state organization, was founded in 1872, and Supreme Council in 1921. Changed name to Benevolent Society of California in 1948. Women were admitted in 1945. Merged with the Uniao Portuguesa Continental do Estado da California (f.1917) in 1957 to become United National Life Insurance Society, later adopted its current name. Reincorporated in 1975. Luso-American Fraternal Federation founded in 1957 to administer fraternal aspect. Administers Luso-American Educational Foundation which grants scholarships to students interested in Portuguese history and culture. Headquarters in Oakland, lodges called "Subordinate lodges" which were present in California, Nevada, Massachusetts, Connecticut, and Rhode Island. In 1978 it had 14,000 members. In 1994 it was reported to have 15,000. Membership is open to Americans of Portuguese descent or birth. Society of the Holy Spirit of the State of California - Founded in Santa Clara, California, in 1895. Headquartered in Santa Clara. Lodges are called Subordinate Councils; the highest is known as the "Supreme Council" which holds a convention annually. Membership is open to all. 1979 membership 11,500, a slight increase since 1972. There is a ritual with provisions for questions and answers, hymns pledges, and passwords.
Elevated ammonia can therefore be detected in patients with urea cycle disorders, as well as other conditions involving liver failure. Enzyme testing is performed for a wide range of metabolic disorders to confirm a diagnosis suspected based on screening tests.
Microscopy is a category of characterization techniques which probe and map the surface and sub-surface structure of a material. These techniques can use photons, electrons, ions or physical cantilever probes to gather data about a sample's structure on a range of length scales. Some common examples of microscopy techniques include:
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.